APOBEC3B and cancer: The EGFR sequence is frequently altered in multiple cancers, and if B-Myb indeed regulates A3B expression and somatic mutations are mediated via EGFR activity, this could favor the clinical tack of inhibiting EGFR signaling in cancer therapeutics.